In animal experiments, SGLT2 inhibitors were shown to improve streptozotocin-induced hyperglycemia and attenuate endothelial dysfunction by at least partially reducing oxidative stress during hyperglycemia 22. This evidence concerns the gene SLC5A2 and Hyperglycemia.